Strategic Moves and Steady Growth Define Petershill’s Q1
Petershill Partners’ Q1 2025 update reveals a business deftly balancing portfolio optimisation with disciplined growth. Let’s unpack the numbers and narratives shaping this alternative asset manager’s trajectory.
The Headline Acts: AuM Dynamics and Strategic Swaps
The firm reported $339bn in aggregate Partner-firm AuM – a modest 1% quarterly increase but a robust 9% year-on-year climb. However, the real story lies beneath:
- Fee-paying AuM dipped 2% QoQ to $234bn, primarily due to the $726m General Catalyst stake sale
- Organic gross fee-eligible AuM raised held steady at $7bn
- New acquisition Frazier Healthcare Partners ($5.5bn AuM) signals focus on specialist sectors
Peeling back the disposal impact reveals stronger fundamentals: adjusted for sold stakes, fee-related earnings (FRE) actually grew 12% year-on-year.
Financial Performance: Margins and Maneuvers
Management fees of $93m (down 3% YoY) mask a 14% underlying growth when excluding disposed assets. The real star? Partner Distributable Earnings surged 28% to $73m, driven by:
- $26m Realised Performance Revenues (including $19m from disposals)
- Maintained 85-90% EBIT margin guidance – enviable in any market
The 62% premium achieved on the General Catalyst disposal isn’t just a win – it’s a masterclass in timing exits.
Capital Allocation: Selling High, Buying Smart
Petershill’s Q1 moves read like a playbook for volatile markets:
- $726m General Catalyst partial exit – crystalising gains while markets permit
- $330m Frazier Healthcare acquisition – doubling down on recession-resilient sectors
- $151m special dividend – rewarding shareholders while maintaining dry powder
This isn’t just portfolio management – it’s capital judo, using market momentum to reposition strategically.
2025 Outlook: Confidence Amid Uncertainty
Despite acknowledging “increased economic uncertainty”, Petershill maintains full-year guidance:
- $20-25bn organic fee-eligible AuM raise
- $180-210m Partner FRE (2024 pro forma: $186m)
- Acquisition spend expected to exceed $300m annual medium-term range
The healthcare sector tilt through Frazier suggests anticipation of sustained demand for medical innovation funding – a savvy hedge against cyclical pressures.
The Bottom Line: Masters of Their Ecosystem
Petershill’s update demonstrates three core strengths:
- Active stewardship: Not passive investors, but partners shaping firm trajectories
- Counter-cyclical agility: Selling at premiums while others hesitate
- Sector foresight: Positioning in healthcare’s structural growth story
As co-CEOs Raissi-Dehkordy and Hamilton Kelly note, this is a firm playing “dynamic capital allocation” at championship level. For investors, Petershill continues offering something rare – exposure to alternative assets without operational heavy lifting. The July AuM update will be telling, but for now, the strategy appears equal parts pragmatic and ambitious.
Disclosure: This analysis dances with the facts but doesn’t marry them – always do your own due diligence before investing.
